Factor IX assays in treated hemophilia B patients
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
Titre :
Factor IX assays in treated hemophilia B patients
Auteur(s) :
Pouplard, Claire [Auteur]
Hôpital Trousseau
Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] [GICC EA 7501]
Jeanpierre, Emmanuelle [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Service d'Hématologie Cellulaire [Lille]
Lasne, Dominique [Auteur]
Laboratoire de Microbiologie Clinique [AP-HP Hôpital Necker-Enfants Malades]
Duchez, Véronique Le Cam [Auteur]
Centre d'Investigation Clinique [CHU Rouen] [CIC Rouen]
Eschwège, Valérie [Auteur]
Service d'Hématologie [CHRU Nancy]
Flaujac, Claire [Auteur]
Centre Hospitalier de Versailles André Mignot [CHV]
Galinat, Hubert [Auteur]
Hôpital de la Cavale Blanche - CHRU Brest [CHU - BREST ]
Harzallah, Ines [Auteur]
Proulle, Valérie [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Smahi, Motalib [Auteur]
Sobas, Frédéric [Auteur]
Hospices Civils de Lyon [HCL]
Ternisien, Catherine [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Toulon, Pierre [Auteur]
Hôpital Pasteur [Nice] [CHU]
Voisin, Sophie [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Nougier, Christophe [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Hôpital Trousseau
Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] [GICC EA 7501]
Jeanpierre, Emmanuelle [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Service d'Hématologie Cellulaire [Lille]
Lasne, Dominique [Auteur]
Laboratoire de Microbiologie Clinique [AP-HP Hôpital Necker-Enfants Malades]
Duchez, Véronique Le Cam [Auteur]
Centre d'Investigation Clinique [CHU Rouen] [CIC Rouen]
Eschwège, Valérie [Auteur]
Service d'Hématologie [CHRU Nancy]
Flaujac, Claire [Auteur]
Centre Hospitalier de Versailles André Mignot [CHV]
Galinat, Hubert [Auteur]
Hôpital de la Cavale Blanche - CHRU Brest [CHU - BREST ]
Harzallah, Ines [Auteur]
Proulle, Valérie [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Smahi, Motalib [Auteur]
Sobas, Frédéric [Auteur]
Hospices Civils de Lyon [HCL]
Ternisien, Catherine [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Toulon, Pierre [Auteur]
Hôpital Pasteur [Nice] [CHU]
Voisin, Sophie [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Nougier, Christophe [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Titre de la revue :
Annales de biologie clinique
Pagination :
41-52
Éditeur :
John Libbey Eurotext
Date de publication :
2019-02
ISSN :
0003-3898
Mot(s)-clé(s) en anglais :
Chromogenic assays
Chronometric assays
Factor IX
Hemophilia B
Chronometric assays
Factor IX
Hemophilia B
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hématologie
Résumé en anglais : [en]
Replacement therapy with plasma-derived or recombinant FIX (pdFIX or rFIX) concentrates is the standard of treatment in patients with hemophilia B. The method predominantly used for measuring factor IX (FIX:C) levels is ...
Lire la suite >Replacement therapy with plasma-derived or recombinant FIX (pdFIX or rFIX) concentrates is the standard of treatment in patients with hemophilia B. The method predominantly used for measuring factor IX (FIX:C) levels is the one-stage clotting assay (OSA) but this method depends on the activated partial thromboplastin time (APTT) reagent and the coagulation analyzer used, and wide variations in the measurements of FIX recovery have been reported with some factor concentrates. The French study group on the biology of hemorrhagic diseases (a collaborative group of the GFHT and MHEMO network), presents a review of the literature and proposals for the monitoring of FIX:C levels in treated hemophilia B patients. The use of OSA calibrated with a plasma reference tested against the current FIX WHO International Standard is recommended for the monitoring of patients treated with pdFIX or rFIX. Chromogenic substrate assays (CSA) are adequate for the monitoring of patients treated with Rixubis®, but data available for Benefix® are currently too limited. For extended half-life rFIX (EHL-rFIX), large discordances in the FIX:C levels measured were evidenced, depending on the method and reagents used. Great attention is therefore required for measuring FIX:C levels by OSA in patients substituted by EHL-rFIX. Commercial kits for CSA are not equivalent, and although potentially useful, they are not validated for all EHL-rFIX. Most of recent studies reported data obtained with spiked plasmas, which deserve to be confirmed on plasma samples collected in treated patients.Lire moins >
Lire la suite >Replacement therapy with plasma-derived or recombinant FIX (pdFIX or rFIX) concentrates is the standard of treatment in patients with hemophilia B. The method predominantly used for measuring factor IX (FIX:C) levels is the one-stage clotting assay (OSA) but this method depends on the activated partial thromboplastin time (APTT) reagent and the coagulation analyzer used, and wide variations in the measurements of FIX recovery have been reported with some factor concentrates. The French study group on the biology of hemorrhagic diseases (a collaborative group of the GFHT and MHEMO network), presents a review of the literature and proposals for the monitoring of FIX:C levels in treated hemophilia B patients. The use of OSA calibrated with a plasma reference tested against the current FIX WHO International Standard is recommended for the monitoring of patients treated with pdFIX or rFIX. Chromogenic substrate assays (CSA) are adequate for the monitoring of patients treated with Rixubis®, but data available for Benefix® are currently too limited. For extended half-life rFIX (EHL-rFIX), large discordances in the FIX:C levels measured were evidenced, depending on the method and reagents used. Great attention is therefore required for measuring FIX:C levels by OSA in patients substituted by EHL-rFIX. Commercial kits for CSA are not equivalent, and although potentially useful, they are not validated for all EHL-rFIX. Most of recent studies reported data obtained with spiked plasmas, which deserve to be confirmed on plasma samples collected in treated patients.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :